Athira Pharma Inc Aktie News

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors.

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira's issued and authorized common stock. Athira's stockholders previously ap...